



(51) International Patent Classification:

C07D 471/16 (2006.01) A61P 31/06 (2006.01)
A61K 31/4745 (2006.01)

(21) International Application Number:

PCT/EP2009/056177

(22) International Filing Date:

20 May 2009 (20.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08382018.3	23 May 2008 (23.05.2008)	EP
08382044.9	17 October 2008 (17.10.2008)	EP
08382057.1	17 October 2008 (17.10.2008)	EP

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALEMPARTE-GALLARDO, Carlos** [ES/ES]; GlaxoSmithKline, Parque Tecnológico de Madrid Calle, Doctor Severo Ocha, Tres Cantos, E-28760 Madrid (ES). **BARFOOT, Christopher** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **BARROS-AGUIRRE, David** [ES/ES]; GlaxoSmithKline, Parque Tecnológico de Madrid Calle, Doctor Severo Ocha, Tres Cantos, E-28760 Madrid (ES). **CACHO-IZQUIERDO, Monica** [ES/ES]; GlaxoSmithKline, Parque Tecnológico de Madrid Calle, Doctor Severo Ocha, Tres Cantos, E-28760 Madrid (ES). **FIANDOR ROMAN, Jose, Maria** [ES/ES]; GlaxoSmithKline, Parque Tecnológico de Madrid Calle, Doctor Severo Ocha, Tres Cantos, E-28760 Madrid (ES). **HENNESSY, Alan, Joseph** [IE/GB]; GlaxoSmithKline, Gunnels Wood Road,

Stevenage Hertfordshire SG1 2NY (GB). **PEARSON, Neil, David** [GB/US]; GlaxoSmithKline, 1250 S. Collegeville Road, P O Box 5089, Collegeville, Pennsylvania 19426 (US). **REMUIÑAN-BLANCO, Modesto, Jesus** [ES/ES]; GlaxoSmithKline, Parque Tecnológico de Madrid Calle, Doctor Severo Ocha, Tres Cantos, E-28760 Madrid (ES).

(74) Agents: **WALKER, Ralph, Francis** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS



(57) Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof; formula (I) (relative chemistry shown) pharmaceutical compositions comprising them, their use in therapy especially against tuberculosis, and methods of preparing them.



-
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*
- Published:**
- *with international search report (Art. 21(3))*